Cyclobenzaprine HCl

Phase 2Small molecule

Takeda

Cyclobenzaprine HCl is one of 2 small molecule programs targeting Acute Stress Reaction. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Stress ReactionRecruiting

Acute Stress ReactionPhase 2

Recruiting

Competition

Competitive Landscape

1 competitor in Acute Stress Reaction

#DrugCompanyPhaseTrials

Minipress

Cyclobenzaprine HCl

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Muscle spasm1 trial

Cyclobenzaprine HCl Extended Release 15 mg Versus Placebo in Treatment of Cervical and/or Lower Back Pain Due to Muscle Spasms of Local Origin

Completed· Takeda logo

Takeda·Phase 3·NCT02814565·180 enrolled

Acute Stress Reaction1 trial

Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL) - (Optimizing Acute Stress Reaction Interventions With TNX-102 SL - OASIS)

Recruiting·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT06636786·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Cyclobenzaprine HCl. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cyclobenzaprine HCl compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cyclobenzaprine HCl. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Takeda

Cyclobenzaprine HCl

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Muscle spasm1 trial

Acute Stress Reaction1 trial

References

Drug Info

Quick Facts

Related News